ACTRN12623000520639招募中1 期
A Randomized, Double-Blind, Parallel group, Comparative Phase I study for the assessment of Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of BP16 versus US licensed - Prolia® and EU approved - Prolia® Following a Single dose (60mg/mL) Subcutaneous Administration in Healthy Male Volunteers
CuraTeQ Biologics Private Ltd.0 个研究点目标入组 204 人开始时间: 2023年5月19日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 204
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 28 Years 至 55 Years（—）
- 性别
- Male
入选标准
- •Each subject must meet all of the following criteria to be randomized in the study.
- •1.Male healthy volunteers of age 28-55 years (Inclusive of both) at the time of signing informed consent.
- •2.Body weight of 60 to 100 kg (both inclusive) and BMI of 18.5 to 30 kg/m2 (both inclusive) at screening visit and day -1 visit.
- •3.Subjects must understand the nature, purpose of the study including possible risks and side effects, agreed to participate in the study and is willing to sign the informed consent form before any study specific procedures.
- •4.Subjects are able to understand and comply with protocol requirements and instructions.
- •5.Subjects with no clinically relevant abnormalities detected during baseline history, physical examination and vital signs (blood pressure, pulse rate, body temperature, including respiratory rate) as judged by the Investigator at screening and day -1 visit.
- •6.Non-smokers or casual smokers who smoke no more than 5 cigarettes (or equivalent quantity of any other nicotine containing substance) per week. Subject must abstain from smoking 48 hours prior to day -1.
排除标准
- •1.Known history or presence of hypersensitivity to the active substance (Denosumab) or to any of the other excipients of investigational products.
- •2.History of cardiovascular, hepatic, ophthalmic, pulmonary, neurological, metabolic, hematological, gastrointestinal, endocrine, immunological, psychiatric or any other disease which in the opinion of the Investigator would make the subject inappropriate for study participation.
- •3.Abnormal and clinically relevant (in the opinion of the Investigator) vital signs, ECG, history of angina, exertional dyspnea, orthopnea, congestive heart failure, or myocardial infarction.
- •4.Have a positive test result for hepatitis B surface antigen (HBsAg), hepatitis C virus, or human immunodeficiency virus (HIV) I and II at screening.
- •5.History of and/or current illness within 28 days prior to the study drug administration that is identified as clinically significant by the investigator.
- •6.Major surgery or major trauma within past six months of screening or anticipated need for any surgery during the study duration.
- •7.History of significant alcohol abuse within 1 year prior to screening or regular use of alcohol within 6 months prior to the screening visit (more than 21 units of alcohol per week [1 unit = 150 mL of wine, 360 mL of beer, or 45 mL of 40% alcohol]).
- •8.Subject with evidence of a condition (psychological, emotional problems, any disorders or resultant therapy) that is likely to invalidate informed consent or limit the ability of the subject to comply with the protocol requirements in the opinion of the investigator.
- •9.Subjects with positive drug test at screening or admission.
- •10.Blood donation within 90 days or platelet/plasma donation within 14 days prior to dosing and during the study.
- •11.Difficulty in blood sampling or difficulty in accessibility of veins.
- •13.A serious infection (associated with housing and/or required intravenous anti-infectives) within 6 months before study drug administration and/or any active infection within 4 weeks of screening requiring oral or systemic antibiotics.
- •14.Subject is not likely to complete the study for whatever reason in the opinion of the investigator.
研究者
相似试验
进行中（未招募）
不适用
A Randomized, Double-Blind, Parallel-Group, Comparative Study of FlexibleDoses of Paliperidone Palmitate and Flexible Doses of Risperidone Long-ActingIntramuscular Injection in Subjects with SchizophreniaMedDRA version: 9.1Level: LLTClassification code 10039626Term: SchizophreniaSchizophreniaEUCTR2006-003560-62-ATJanssen-Cilag International N.V.1,100
进行中（未招募）
不适用
A Randomized, Double-Blind, Parallel-Group, Comparative Study of FlexibleDoses of Paliperidone Palmitate and Flexible Doses of Risperidone Long-ActingIntramuscular Injection in Subjects with SchizophreniaMedDRA version: 9.1Level: LLTClassification code 10039626Term: SchizophreniaSchizophreniaEUCTR2006-003560-62-EEJanssen-Cilag International N.V.1,050
进行中（未招募）
不适用
A Randomized, Double-Blind, Parallel-Group, Comparative Study of FlexibleDoses of Paliperidone Palmitate and Flexible Doses of Risperidone Long-ActingIntramuscular Injection in Subjects with SchizophreniaSchizophreniaEUCTR2006-003560-62-HUJanssen-Cilag International N.V.700
进行中（未招募）
1 期
A Randomized, Double-Blind, Parallel-Group, Comparative Study of FlexibleDoses of Paliperidone Palmitate and Flexible Doses of Risperidone Long-ActingIntramuscular Injection in Subjects with SchizophreniaEstudio Comparativo, Aleatorizado, Doble-Ciego, de Grupos Paralelos entre Diferentes Dosis de Palmitato de Paliperidona y de Risperidona Intramuscular Inyectable de Larga Duración en Sujetos con EsquizofreniaMedDRA version: 9.1Level: LLTClassification code 10039626Term: SchizophreniaSchizophreniaEUCTR2006-003560-62-ESJanssen-Cilag International N.V.
进行中（未招募）
不适用
A Randomized, Double-Blind, Parallel-Group, Comparative Study of FlexibleDoses of Paliperidone Palmitate and Flexible Doses of Risperidone Long-ActingIntramuscular Injection in Subjects with SchizophreniaSchizophreniaEUCTR2006-003560-62-DEJanssen-Cilag International N.V., Turnhoutseweg 30, 2340 Beerse, Belgium1,100